Health Condition 1: J309- Allergic rhinitis, unspecified
Conditions
Interventions
Intervention1: Montelukast plus Bilastine: Tab Montelukast 10 mg + Bilastine 20 mg (FDC) once daily for 4 weeks.
Control Intervention1: Montelukast plus levocetirizine: Tab Montelukast 10 mg + Levocet
Sponsors
Dr Ganesh Dakhale
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients suffering from non-specific allergic rhinitis of either gender, in age group 18 to 65 years. 2. History of intermittent or persistent allergic rhinitis of any severity with no obvious cause prior to inclusion in study. 3. Patients with TNSS greater than 8 not treated with anti-histamines in last 7 days.
Exclusion criteria
Exclusion criteria: 1. History of asthma requiring chronic use of inhaled corticosteroids. 2. Had been unresponsive to anti-histamine in the past. 3. History of allergy to the study medication or unable to tolerate anti-histamines. 4. Use of study drug in last 1 week prior to baseline. 5. Pregnant and nursing women. 6. Subjects with history of significant haematopoietic, hepatic, renal, cardiovascular, neurological, psychiatric or autoimmune disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in total nasal symptom score (TNSS)Timepoint: at baseline, week 2, week 4 | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of adverse events in group A & Group BTimepoint: during 4 weeks of study period;To compare Cost effectiveness ratio between group A & group BTimepoint: at 4 weeks | — |
Countries
India
Contacts
Public ContactDr Ganesh Dakhale
All India Institute of Medical Sciences, Nagpur
Outcome results
None listed